Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
Sponsor: AVM Biotechnology Inc
ClinicalTrials ID:NCT05974410
AVM Biotechnology's program offers AVM0703, a small molecule immunomodulatory drug, to patients with various solid tumors and blood cancers. The treatment includes hydrocortisone and a proton pump inhibitor. Eligibility criteria are not specified. Side effects are mainly mild, such as itching and low-grade insomnia. The program operates under FDA's Expanded Access Program.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.
Eligibility Criteria
Inclusion Criteria
Exclusion Criteria
Get This Program In Your Inbox
You can sign up and apply your patients for this program.